Clinical Trial Update: A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy

View source ↗

Summary

This clinical trial in adults with type 2 diabetes evaluates the risk of non-alcoholic fatty liver disease in clinical practice and assesses the usefulness of a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)
• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: Boryung Pharmaceutical Co., Ltd | Conditions: Type 2 Diabetes | Status: RECRUITING